Myriad Genetics Inc
MYGN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$59.10 | Wmnvp | Xfdmvyjw |
Taking a Fresh Look at Myriad Genetics; No-Moat Company Remains Overvalued With FVE at 21.50
After taking a fresh look at Myriad Genetics, we have assigned it with a fair value estimate of $21.50, a no-moat rating, and a stable moat trend. Myriad’s product portfolio includes hereditary cancer, tumor profiling, prenatal, and pharmacogenomics in which Myriad aims to use genetic insights to improve patient care while lowering healthcare costs.